Le Lézard
Classified in: Health, Science and technology
Subject: TDS

Multiple Learning Credits Available for Attendees of Virtual HIPAA Privacy and Security Summit November 12, 2020

WILMINGTON, Del., Oct. 27, 2020 /PRNewswire-PRWeb/ -- The Virtual HIPAA Privacy and Security Summit is a joint effort of Delaware Law School and First Healthcare Compliance to provide resources for attorneys and professionals facing the challenges of HIPAA compliance. The online event will be held on November 12, 2020, from 12:00 pm ET until 5:20 pm ET. Registration is available to the public.

Educational discussions will be coupled with multiple opportunities for learning credits. Attendees are eligible to receive 5 CLE credits (4 substantive and 1 ethics) in Delaware, New Jersey, and Pennsylvania. This program has been reviewed and approved for 5.0 Continuing Education Unit(s) by PAHCOM and Practice Management Institute®. The Compliance Certification Board (CCB)® has approved this event for up to 6.0 live CCB CEUs based on a 50-minute hour. Continuing Education Units are awarded based on individual attendance records. Granting of prior approval in no way constitutes endorsement by CCB of this event content or of the event sponsor.

Sponsors of this event include Weiner Benefits Group, SymbianceHR, and PAHCOM while prizes will be awarded from Practice Management Institute® and the BBC Tavern and Grill.

Schedule for the virtual HIPAA Privacy and Security Summit:

12:00- 12:20 Welcome and Panel Discussion with FAQs
First Healthcare Compliance and Delaware Law School GICLS

12:20- 12:50 Distinguished Speaker
John Shegerian, Executive Chairman of ERI
Hardware Data Hacking and HIPAA: the Overlooked Cybercrime

12:50-12:55 Q & A/short break

12:55- 1:55 Rachel V. Rose, JD, MBA
HIPAA Hot Topics

1:55-2:00 Q & A/short break

2:00 - 3:00 Kathleen McNicholas, MD, JD, CHC, CCEP
Ethics and 20 years of HIPAA

3:00 - 3:05 Q & A/short break

3:05-4:05 Rebecca Rakoski, Esq.
Updates on Data Privacy Regulations

4:05 - 4:10 Q& A/short break

4:10-5:10 Iliana Peters, Esq.
What's your nightmare? Cyber-attacks during the COVID public health emergency

5:10 -5:20 HIPAA recap

About Delaware Law School: Widener University is a metropolitan university that connects curricula to social issues through civic engagement. Dynamic teaching, active scholarship, personal attention, applied leadership, and experiential learning are key components of the Widener experience. Delaware Law School is the First State's only law school, providing a Juris doctor, legal graduate and paralegal degree programs with an emphasis on developing legal professionals who reflect the Delaware Way and its traditions of civility, integrity and mutual respect. The school offers signature programs in corporate and business law, environmental law, family health law and policy, trial advocacy, and dignity rights.

About First Healthcare Compliance: Founded in 2012 by a nurse attorney, the First Healthcare Compliance software solution creates confidence among compliance professionals through education, resources, and support in the areas of HIPAA, OSHA, human resources compliance, and fraud waste and abuse laws. Serving clients across the United States, the company's evolving platform provides real-time insight for board reporting and across multiple locations. For more information please visit https://1sthcc.com/


SOURCE First Healthcare Compliance

These press releases may also interest you

at 18:05
GlycoMimetics' product candidate uproleselan ? when added to a combination therapy of venetoclax and a hypomethylating agent (HMA) ? was shown today in an oral presentation to break chemoresistance by dramatically and significantly reducing tumor...

at 18:00
Quanta X Technology, the parent company of QuantaDose, CEO Katie Webb suggests, "Anyone in Santa's shoes gifting a UVC device to a friend or family member needs to make sure the UV-C device is real, and they also need to understand the potential...

at 17:00
63% response rate in patients treated with the highest reported dose Among all patients responding to treatment, 95% experienced a very good partial response or better; among responding patients with ?6 months of follow-up, 83% have ongoing responses...

at 16:30
The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from an ongoing Phase 1 first-in-human dose escalation study (NCT03145181) of teclistamab (JNJ-64007957) for the treatment of relapsed or refractory multiple...

at 15:30
Gracell Biotechnologies Inc. ("Gracell"), a global clinical-stage biopharmaceutical company dedicated to developing highly efficacious and affordable cell therapies for the treatment of cancer, today announced an interim readout to evaluate the...

at 15:05
bluebird bio, Inc. today presented updated long-term efficacy and safety results reflecting up to six years of data for betibeglogene autotemcel gene therapy (beti-cel; formerly LentiGlobintm for ?-thalassemia) in patients with transfusion-dependent...

News published on 27 october 2020 at 02:00 and distributed by: